177Lu-PSMA-617 approved for use in patients with PSMA+ mCRPC
As of the 23rd March 2022, the U.S. Food and Drug Administration (FDA) has approved 177Lu-PSMA-617 (a.k.a. Lu 177 Vipivotide…
Top 5 picks from ASCO GU 2022
Catch the latest updates in GU with VJOncology from the American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium 2022!
PHS290: a novel scoring algorithm provides a promising approach to screening for prostate cancer in diverse populations
A novel polygenic hazard score (PHS), PHS290, accurately predicts lifetime risks of developing metastatic or terminal prostate cancer across multiple…
Key updates from EAU 2021
VJOncology presents highlights from this year’sEuropean Association of Urology (EAU) Virtual Meeting 2021!
Top picks from ASCO 2021
VJOncology presents highlights from this year’s virtual American Society of Clinical Oncology (ASCO) annual meeting!
FDA gives mitomycin gel green light for low-grade upper tract urothelial cancer
April 15th saw the Food and Drug Administration (FDA) approval of mitomycin gel (Jelmyto) for the treatment of low-grade upper…
Multi-cancer detection and localization for more than 50 cancer types
The early detection of cancer improves outcomes for patients – in terms of both reducing treatment burden and improving the…
Darolutamide gets the OK in Europe for nmCRPC
Metastatic castration-resistant prostate cancer (mCRPC) has limited treatment options and metastatic growth is associated with increased comorbidities. To put the…